Wall Street Zen upgraded shares of Aclarion (NASDAQ:ACON – Free Report) from a sell rating to a hold rating in a research report report published on Saturday morning.
Aclarion Stock Up 2.8%
NASDAQ:ACON opened at $6.66 on Friday. Aclarion has a fifty-two week low of $6.20 and a fifty-two week high of $3,499.51. The stock’s 50-day moving average is $8.16 and its two-hundred day moving average is $404.49.
Aclarion (NASDAQ:ACON – Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($9.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1,447.20) by $1,437.88. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Aclarion had a negative return on equity of 422.87% and a negative net margin of 12,845.05%. As a group, research analysts expect that Aclarion will post -263.33 EPS for the current year.
About Aclarion
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Further Reading
- Five stocks we like better than Aclarion
- What is an Earnings Surprise?
- Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead
- Most Volatile Stocks, What Investors Need to Know
- Top 3 ETFs Defense Hawks Are Buying
- How to Buy Cheap Stocks Step by Step
- Zscaler Will Hit $360 Soon: Here’s the How and Why
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
